Appendix B Sources of evidence considered by the Committee

Appendix B Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Systematic Reviews Centre for Reviews and Dissemination, University of York:

Collins R, Fenwick E, Trowman R et al. A systematic review and economic model of the effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer, September 2005.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the appraisal consultation document. Consultee organisations are provided with the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsors:

  • Sanofi-Aventis.

II) Professional/specialist and patient/carer groups:

  • British Association of Urological Nurses

  • British Association of Urological Surgeons

  • British Geriatrics Society

  • British Oncological Association

  • British Oncology Pharmacy Association (BOPA)

  • British Prostate Group

  • British Psychosocial Oncology Society (BPOS)

  • Cancer Research UK

  • Cancer Voices

  • CancerBACUP

  • Department of Health

  • Erewash PCT

  • Greenwich PCT

  • Long-term Medical Conditions Alliance

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • National Cancer Alliance

  • National Council for Hospice and Specialist Palliative Care Services

  • Prostate Cancer Charity

  • Prostate Cancer Support Association

  • Prostate Help Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Royal College of Surgeons

  • Royal Pharmaceutical Society

  • Tenovus Cancer Information Centre

  • Welsh Assembly Government.

III) Commentator organisations (without the right of appeal):

  • Baxter Healthcare

  • Board of Community Health Councils in Wales

  • British National Formulary

  • Institute of Cancer Research

  • Mayne Pharma

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Collaborating Centre for Cancer

  • National Coordinating Centre for Health Technology Assessment

  • National Public Health Service for Wales

  • NHS Centre for Reviews & Dissemination –York

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Pfizer

  • Prostate Cancer Guideline Development Group

  • Wyeth Pharmaceuticals.

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on docetaxel for the treatment of hormone-refractory metastatic prostate cancer by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document:

  • Mr Noel Clarke, Consultant Urologist, British Association of Urological Surgeons, MRC Clinical Trials Unit – Clinical Specialist.

  • Professor Jonathan Waxman, Professor of Oncology, Imperial College of Science Technology and Medicine, nominated by the Prostate Cancer Charity – Clinical Specialist.

  • Mr Ian Gooding, nominated by Tenovus Cancer Information Centre – Patient Expert.

D. The following individual representing the National Collaborating Centre responsible for developing the Institute's clinical guideline on prostate cancer was invited to attend the Appraisal Committee's meetings on the appraisal consultation document and final appraisal determination to contribute as an advisor.

  • Dr John Graham, Consultant in Clinical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow